Table 1.
Therapy | Target | Outcome | +/− | Model | Ref. |
---|---|---|---|---|---|
Temozolomide + doxorubicin | P-gp | Increased survival | + | Rats | 263 |
Palbociclib | CDK4/6 | Activity limited by P-gp | − | Mice | 264 |
LIUS | P-gp and MDR1 | Apoptosis and CNS delivery | + | Rats and C6 cells | 266 |
FGK45 | CD40 | Increased survival Decreased proliferation |
+ | Mice | 267 |
γ9δ2 T cells | IFN γ | Increased cytotoxicity | + | GBM cells | 268 |
miROPN | OPN | Less stem cell markers Less proliferation Increased survival |
+ | Mice | 270 |
CAR-transduced T cells | PDPN | Inhibition of intracranial glioma xenografts growth | + | Mice | 273 |
LRIG1 | Oncogenic receptor tyrosine kinases | Slowing of tumor growth. Apoptosis | + | Mice | 275 |
VB-111 | Endothelial cells | Decreased tumor vasculature and growth | + | Rats | 276 |
Decorin | EGFR, TGF- beta and p21 | Cellular differentiation Survival |
+ | Mice | 278 |
HDAC6i | HDAC6 | Increased survival | + | Mice | 280 |
oHSV | nectin-1 (CD111) | Increased cytotoxicity | + | Pediatric patients | 281 |
HDACi + Delta24-RGD | HDAC and p16INK4/Rb pathway | Apoptosis and necrosis | + | Patient-derived GSCs | 282 |
PDNCs | CNS delivery | Increased trans-BBB delivery and CNS retention time | + | Rats | 284 |
Lf/FA/PLGA NPs | VEGF secretion | Less proliferation | + | U87MG cells | 285 |
C-SLN | CNS delivery | Improved delivery and cytotoxicity | + | Mice | 286 |
RDG | CNS delivery | Increased delivery and CNS retention | + | Mice | 287 |
HA-paclitaxel nanoconjugate | Microtubules | Survival | + | Mice | 288 |
VD3NPs combined with doxorubicin or epirobicin | Sphingomyelin pathway | Increase in drug resistance | − | C6 glioma cells | 290 |
+ indicates a favorable outcome.
−indicates an unfavorable outcome.